Candesartan
Atacand, Blopress, Candeblo, Candesartan · ATC code C09CA06
Also known as: Kandesartan, Candésartan, Candesartán · Brand names: Atacand, Blopress, Candaxiro, Candecor, Candesartancilexetil Ct, Candesartancilexetil Genmed, Candesartancilexetil Hennig, Candesartancilexetil Mylan, Candeblo, Ayra, Candecard, Candenact, Candexil, Cantab, Larmoni …
- Key facts
- Active substance
- Candesartan
- ATC code
- C09CA06
- Authorisation
- authorised nationally; no central EU authorisation
- Information as of
- 2026-11-03
Boxed warning
• When pregnancy is detected, discontinue candesartan cilexetil tablets as soon as possible [see Warnings and Precautions (5.1)].
• Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].
Key facts
Candesartan (as candesartan cilexetil) is an oral angiotensin II receptor blocker (ARB). Per the US label it is used for hypertension in adults and children 1 to <17 years and for heart failure with reduced ejection fraction in adults.
What it is used for
- Hypertension in adults and children 1 to <17 years of age, alone or with other antihypertensives
- Heart failure (NYHA class II-IV) with ejection fraction ≤40% in adults, to reduce cardiovascular death and heart failure hospitalisations; adds benefit on top of an ACE inhibitor
Dosing
- Adult hypertension: usual start 16 mg once daily (not volume depleted); total 8 mg to 32 mg per day, once or twice daily
- Moderate hepatic impairment: start with 8 mg; correct volume depletion before starting
- Heart failure: start 4 mg once daily, double about every 2 weeks as tolerated to a target of 32 mg once daily
- Children 1 to <6 years: 0.05 to 0.4 mg/kg per day, start 0.2 mg/kg (oral suspension)
- Children 6 to <17 years: less than 50 kg 2 to 16 mg per day (start 4 to 8 mg); greater than 50 kg 4 to 32 mg per day (start 8 to 16 mg)
- Not for children <1 year or children with GFR less than 30 ml/min/1.73 m²
Contraindications
- Hypersensitivity to candesartan
- Co-administration with aliskiren in patients with diabetes
Important warnings
- Boxed warning: fetal toxicity; drugs acting on the renin-angiotensin system can injure and kill the fetus; discontinue as soon as pregnancy is detected
- Symptomatic hypotension, especially with volume or salt depletion and during major surgery/anaesthesia
- Impaired renal function, including acute renal failure (renal artery stenosis, severe heart failure, volume depletion)
- Hyperkalaemia; monitor serum potassium periodically
- Children <1 year must not receive candesartan (effects on immature kidneys)
Side effects
- Hypertension trials: upper respiratory tract infection (6%), dizziness (4%), back pain (3%), pharyngitis, rhinitis
- Heart failure (CHARM): hypotension (18.8% vs 9.8% placebo), abnormal renal function (12.5%), hyperkalaemia (6.3%)
- Postmarketing (very rare): angioedema, hepatitis, neutropenia/agranulocytosis, hyponatraemia, cough, rash
Interactions
- Potassium-sparing diuretics, potassium supplements, salt substitutes: hyperkalaemia
- Lithium: increased serum lithium and toxicity; monitor levels
- NSAIDs including COX-2 inhibitors: worsening renal function and attenuated antihypertensive effect
- Dual RAS blockade (ACE inhibitor, aliskiren): more hypotension, hyperkalaemia and renal changes; avoid aliskiren with GFR <60 ml/min; triple combination with an ACE inhibitor and a mineralocorticoid receptor antagonist generally not recommended
Pregnancy and breastfeeding
- Use in the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death (oligohydramnios, skull hypoplasia, renal failure)
- Discontinue as soon as pregnancy is detected; observe exposed infants for hypotension, oliguria and hyperkalaemia
- Unknown whether excreted in human milk; decide between nursing and the drug
Summary of the official product information, written with AI on 2026-11-03. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Patient information (US)
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
Germany
- AtacandCheplapharm Arzneimittel Gmbh · 2 register entries
- BlopressCheplapharm Arzneimittel Gmbh · 1 register entry
- CandaxiroMedical Valley Invest Ab · 1 register entry
- CandecorTad Pharma Gmbh · 1 register entry
- Candesartan1 A Pharma Gmbh, Ratiopharm Gmbh, Puren Pharma Gmbh & Co. Kg, Devatis Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Zentiva Pharma Gmbh, Basics Gmbh, Aliud Pharma Gmbh, Biomo Pharma Gmbh, Hexal Ag, Viatris Germany Gmbh, Stadapharm Gmbh, Betapharm Arzneimittel Gmbh, Tad Pharma Gmbh, Aaa-Pharma Gmbh, Abz-Pharma Gmbh · 19 register entries
- Candesartancilexetil CtAbz-Pharma Gmbh · 1 register entry
- Candesartancilexetil GenmedGenmed Pharma Gmbh · 2 register entries
- Candesartancilexetil HennigHennig Arzneimittel Gmbh & Co. Kg · 1 register entry
- Candesartancilexetil MylanViatris Germany Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03
Austria
- AtacandCheplapharm Arzneimittel Gmbh · 1 register entry
- BlopressCheplapharm Arzneimittel Gmbh · 1 register entry
- CandebloG.L. Pharma Gmbh · 1 register entry
- Candesartan1a Pharma Gmbh, Teva B.V, Genericon Pharma Gesellschaft M.B.H., +pharma Arzneimittel Gmbh, Actavis Group Ptc Ehf., Sandoz Gmbh, Stada Arzneimittel Gmbh, A-Med Gmbh, G.L. Pharma Gmbh, Krka, D.D., Novo Mesto · 12 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03
Turkey
- AtacandBMED İLAÇ DANIŞMANLIK SAĞLIK ÜRÜN VE HİZMETLERİ TİC. LTD. ŞTİ. · 4 register entries
- AyraSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 5 register entries
- CandecardSANDOZ İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
- CandenactHUMANİS SAĞLIK A.Ş. · 8 register entries
- CandexilDEVA HOLDİNG A.Ş. · 3 register entries
- CantabNOBEL İLAÇ SAN. VE TİC. A.Ş. · 12 register entries
- LarmoniSENSYS İLAÇ SAN. A.Ş. · 6 register entries
- TensartABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 5 register entries
- UcandNOBEL SAĞLIK ÜRÜNLERİ LTD ŞTİ · 12 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-11-03
Brand names in 27 more European countries
- Belgium
- Atacand, Candesartan Eg, Candesartan Eurogenerics, Candesartan Krka, Candesartan Sandoz, Candesartan Teva
- Bulgaria
- Атаканд, Кандекон, Кандесартан Актавис, Кандестар, Кантаб, Карбис, Карзап, Репидо
- Croatia
- Kandepres, Karbis
- Cyprus
- Atacand, Candepress, Candesartan Krka, Candesartan Tad
- Czechia
- Canocord, Carzap, Casaro
- Denmark
- Atacand, Candemox, Canderion, Candesartan "medical Valley", Candesartan Krka, Candesartan Liconsa, Candesartan Orion, Candesartan Stada, Candesartan Viatris, Kairasec, Kandrozid
- Estonia
- Atacand, Canocord, Carzan, Prescanden
- Finland
- Atacand, Candemox, Canderion, Candesarstad Stada Arzneimittel, Candesartan Actavis, Candesartan Krka, Candesartan Orion, Candesartan Stada Stada, Candestad, Candexetil Ratiopharm, Kandrozid
- France
- Atacand, Candesartan Arrow, Candesartan Biogaran, Candesartan Cristers, Candesartan Eg, Candesartan Evolugen, Candesartan Hcs, Candesartan Sandoz, Candesartan Teva, Candesartan Viatris, Candesartan Zentiva, Candesartan Zydus France, Candésartan Eg Labo, Kenzen
- Greece
- Atacand, Fyronexe
- Hungary
- Karbis
- Iceland
- Candesartan Stada, Candpress, Kairasec
- Ireland
- Atacand, Blopress, Candesartan Accord Healthcare Ireland, Candesartan Clonmel, Candesartan Krka, Candist
- Italy
- Blopress, Candesartan Alter, Candesartan Aurobindo, Candesartan Doc, Candesartan Eg, Candesartan Hcs, Candesartan Mylan, Candesartan Pensa, Candesartan Sandoz, Candesartan Teva Italia, Candesartan Zentiva, Flortitens, Ratacand
- Latvia
- Canocord, Carzan
- Lithuania
- Canocord, Carzan
- Luxembourg
- Atacand, Candesartan Eg, Candesartan Eurogenerics, Candesartan Ratiopharm
- Malta
- Candesartan, Candist
- Netherlands
- Atacand, Candesartan Cilexetil Aurobindo, Candesartan Cilexetil Devatis, Candesartan Cilexetil Focus Care, Candesartan Cilexetil Krka, Candesartan Cilexetil Medical Valley, Candesartan Cilexetil Sandoz, Candesartan Cilexetil Teva, Candesartan Cilexetil Torrent, Candesartan Cilexetil Viatris, Candesartan Cilexetil Xiromed, Kairasec
- Norway
- Atacand, Candesartan Krka, Candesartan Medical Valley, Candesartan Orion, Candesartan Sandoz, Candesartan Stada, Kandrozid
- Poland
- Atacand, Candepres, Carzap, Casaro, Kandesar, Karbis, Ranacand
- Portugal
- Atacand, Blopress, Candesartan, Sartydox
- Romania
- Atacand, Candesartan, Canzeno, Karbis, Tandesar
- Slovakia
- Atacand, Candesartan Ratiopharm, Candesartan Sandoz, Carzap, Casaro, Kandesartan Stada, Karbis, Stadacand
- Slovenia
- Atacand, Candea, Candecor
- Spain
- Atacand, Blopress, Candesartan Pensa, Candesartan Teva, Candesartán Krka, Candesartán Almus, Candesartán Alter, Candesartán Aurovitas, Candesartán Cinfa, Candesartán Combix, Candesartán Kern Pharma, Candesartán Mabo, Candesartán Normon, Candesartán Sandoz, Candesartán Stada, Candesartán Stadafarma, Candesartán Sun, Candesartán Tarbis, Candesartán Teva, Candesartán Viatris, Karbis, Parapres
- Sweden
- Atacand, Canderion, Candesarstad, Candesartan Devatis, Candesartan Krka, Candesartan Medical Valley, Candesartan Orion, Candesartan Reddy, Candesartan Sandoz, Candesartan Stada Stada, Candexetil, Kairasec, Kandrozid
EMA – Article 57 product data (EU/EEA), 2026-11-03
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- U.S. Food and Drug Administration. CANDESARTAN CILEXETIL (Alembic Pharmaceuticals Limited) – Prescribing Information, 2023-01-27. DailyMed (NLM), 2026-11-03. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5b43fa0-6678-4219-99f1-10d273d49baf
- EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-11-03. https://www.titck.gov.tr/dinamikmodul/85
Editorial: Medelix editorial team · last updated 2026-11-03 · How these pages are made · Report an error
Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.